RedHill Biopharma (RDHL) Posts Smaller Q1 Loss

RedHill Biopharma (NASDAQ: RDHL) reported Q1 EPS of ($0.03), $0.20 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $18.2 million versus the consensus estimate of $24.3 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Dick's Sporting Goods: Analyst sees long-term upside outweighing near-term noise
• Niu Technologies (NIU) Reports Q2 Loss of $0.19
• Jerash Holdings (US), Inc. (JRSH) Tops Q1 EPS by 5c ; Offers Guidance